Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study

被引：0
|
作者：
Genovese, Mark C. [1 ]
Kremer, Joel [2 ]
Zhong, Sheng [3 ]
Friedman, Alan [3 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Albany Med Coll, Albany, NY 12208 USA
[3] AbbVie Inc, N Chicago, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
509
引用
收藏
页数：4
相关论文
共 50 条
  • [1] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN LABEL EXTENSION STUDY
    Genovese, M. C.
    Kremer, J.
    Zhong, S.
    Friedman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 979 - 979
  • [2] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN-LABEL EXTENSION STUDY
    Genovese, Mark C.
    Kremer, Joel
    Zhong, Sheng
    Friedman, Alan
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S85 - S85
  • [3] Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
    Genovese, Mark C.
    Smolen, Josef S.
    Weinblatt, Michael E.
    Burmester, Gerd R.
    Meerwein, Sebastian
    Camp, Heidi S.
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Pangan, Aileen L.
    Jungerwirth, Steven
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2857 - 2866
  • [4] CHANGES IN C-REACTIVE PROTEIN AND LIPID LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABT-494, A SELECTIVE JAK-1 INHIBITOR
    Nurmohamed, M.
    Zhang, Y.
    Lin, J.
    Camp, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 280 - 280
  • [5] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
    Genovese, M. C.
    Smolen, J. S.
    Weinblatt, M. E.
    Meerwein, S.
    Camp, H. S.
    Wang, L.
    Othman, A. A.
    Khan, N.
    Jungerwirth, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 141 - 142
  • [6] SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
    Sandborn, William J.
    Feagan, Brian G.
    Panes, Julian
    D'Haens, Geert R.
    Colombel, Jean Frederic
    Zhou, Qian
    Huang, Bidan
    Enejosa, Jeffrey V.
    Pangan, Aileen L.
    Lacerda, Ana P.
    GASTROENTEROLOGY, 2017, 152 (05) : S1308 - S1309
  • [7] A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
    Kremer, Joel M.
    Emery, Paul
    Camp, Heidi S.
    Friedman, Alan
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Pangan, Aileen L.
    Jungerwirth, Steven
    Keystone, Edward C.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2867 - 2877
  • [8] PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE SELECTIVE JAK1 INHIBITOR, ABT-494, IN HEALTHY VOLUNTEERS AND SUBJECTS WITH RHEUMATOID ARTHRITIS
    Mohamed, M. -E.
    Camp, H.
    Jiang, P.
    Padley, R.
    Asatryan, A.
    Othman, A. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 258 - 258
  • [9] Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
    Mohamed, Mohamed-Eslam F.
    Camp, Heidi S.
    Jiang, Ping
    Padley, Robert J.
    Asatryan, Armen
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2016, 55 (12) : 1547 - 1558
  • [10] Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
    Mohamed-Eslam F. Mohamed
    Heidi S. Camp
    Ping Jiang
    Robert J. Padley
    Armen Asatryan
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2016, 55 : 1547 - 1558
12345